Given a recent update from the PLCO trial reporting that over 90% of men in the 'usual care' arm underwent some degree of PSA testing, the PLCO can no longer accurately be called a

trial of screening versus no screening — nor can it be included as such in meta-analyses or guideline statements. Access through your institution Buy or subscribe This is a preview of

subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only

$17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout

Task Force recommendation statement. _Ann. Intern. Med._ 157, 120–134 (2012). Article  Google Scholar  * Schröder, F. H. _ et al_. Screening and prostate- cancer mortality in a randomized

European study. _N. Eng. J. Med._ 360, 1320–1328 (2009). Article  Google Scholar  * Lamerato, L. E., Marcus, P. M., Jacobsen, G. & Johnson, C. C. Recruitment in the Prostate, Lung,

Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the first phase of recruitment at Henry Ford Health System. _Cancer Epidemiol. Biomarkers Prev._ 17, 827–833 (2008). Article  Google

Scholar  * Grubb, R. L. _ et al_. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening

in a randomized trial. _BJU Int._ 102, 1524–1530 (2008). Article  Google Scholar  * Ilic, D., Neuberger, M. M., Djulbegovic, M. & Dahm, P. Screening for prostate cancer. _Cochrane

Database Syst. Rev._ 1, CD004720 (2013). Google Scholar  * Pinsky, P. F. _ et al_. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and

Ovarian (PLCO) Cancer Screening Trial. _Clin. Trials_ 7, 303–311 (2010). Article  Google Scholar  * Andriole, G. L. _ et al_. Prostate cancer screening in the randomized Prostate, Lung,

Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. _J. Natl Cancer Inst._ 104, 1–8 (2012). Article  Google Scholar  * Shoag, J. E., Mittal, S.

& Hu, J. C. Reevaluating PSA testing rates in the PLCO trial. _N. Engl. J. Med._ 374, 1795–1796 (2016). Article  Google Scholar  * Jemal, A. _ et al_. Prostate cancer incidence and PSA

testing patterns in relation to USPSTF screening recommendations. _JAMA_ 314, 2054–2061 (2015). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS

* Matthew R. Cooperberg is at the Departments of Urology and Epidemiology & Biostatistics, UCSF Helen Diller Family Comprehensive Cancer Center, 550 16th Street, Box 1695, San Francisco,

California 94143-1695, USA., Matthew R. Cooperberg Authors * Matthew R. Cooperberg View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR

Correspondence to Matthew R. Cooperberg. ETHICS DECLARATIONS COMPETING INTERESTS The author declares no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Cooperberg, M. Why the prostate arm of the PLCO trial failed and what it has taught us. _Nat Rev Urol_ 13, 439–440 (2016).

https://doi.org/10.1038/nrurol.2016.116 Download citation * Published: 12 July 2016 * Issue Date: August 2016 * DOI: https://doi.org/10.1038/nrurol.2016.116 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative